GleamWall
中文EN

MNOV MEDICINOVA INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1226616 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.2%
TTM EPS YoY16.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,232.2%
Net margin-1,127.0%
FCF margin-1,047.7%
EBITDA margin-1,230.3%

Returns

ROE-24.8%
ROA-22.7%
ROIC (approx.)-78.4%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.00x
Current ratio8.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$409,657—
R&D expense$6.70M$6.80M
SG&A expense$6.16M$5.48M
Operating income-$13.28M-$12.68M
Pretax income-$11.99M-$11.04M
Income tax$5,994$5,537
Net income-$12.00M-$11.05M
EBITDA-$13.26M-$12.65M
EPS (basic)-0.24-0.23
EPS (diluted)-0.24-0.23
Weighted avg. shares (diluted)49.06M49.05M
Balance sheet
Cash & equivalents$30.81M$40.36M
Receivables$0$0
Current assets$30.99M$41.07M
PP&E, net$8,340$25,507
Goodwill$9.60M$9.60M
Total assets$45.60M$55.88M
Current liabilities$3.80M$2.96M
Total liabilities$4.02M$3.37M
Shareholders' equity$41.59M$52.50M
Shares outstanding49.22M49.05M
Cash flow statement
Operating cash flow-$9.81M-$10.64M
Capital expenditure$2,899$895
Free cash flow-$9.81M-$10.64M
Investing cash flow-$2,899-$697
Financing cash flow$244,018$0
Depreciation & amortization$20,099$21,077
Stock-based compensation$829,095$1.19M

Free plan shows the latest 2 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.